

## INVESTOR CONFERENCE CALL – TO BE RESCHEDULED

**Adelaide, Australia, 4 February 2025:** Australian hi-tech company Micro-X Ltd (ASX:MX1) (**Micro-X** or the **Company**), a leader in cold cathode x-ray technology for health and security markets globally, advises that the Investor Conference Call will be rescheduled to a later date.

In the Company's Quarterly lodged with the ASX on 31 January 2025, it was advised that the Company's Chief Executive, Kingsley Hall would host a Quarterly Investor Call at 9.00am AEDT on 5 February 2025, to discuss the Company's activities and results and the business outlook.

The Company is currently in advanced stages of preparing to execute a capital raising and accordingly, the Quarterly Investor Call will be rescheduled to a later date. Details of the new time and date will be advised as soon as possible.

This ASX Announcement is authorised by the Company Secretary of Micro-X.

– ENDS –

### About Micro-X

Micro-X Limited is an ASX listed hi-tech company developing and commercialising a range of innovative products for global health and security markets, based on proprietary cold cathode, carbon nanotube (CNT) emitter technology. The electronic control emitters with this technology enables x-ray products with significant reduction in size, weight, and power requirements, enabling greater mobility and ease of use in existing x-ray markets and a range of new and unique security applications. Micro-X has a fully vertically integrated design and production facility in Adelaide, Australia. A growing technical and commercial team based in Seattle is rapidly expanding Micro-X's US business.

Micro-X's product portfolio spans a number of high margin, product applications in health and security. The first mobile digital radiology products are currently sold for diagnostic imaging in global healthcare, military and veterinary applications. The US Department of Homeland Security has contracted Micro-X to design a next-generation Airport security checkpoint. A miniature brain CT imager for pre-hospital stroke diagnosis in ambulances, is being developed with funding from the Australian Government's Medical Research Future Fund. In November 2024, US Government agency ARPA-H contracted Micro-X to develop a full-body CT.

For more information visit: [www.micro-x.com](http://www.micro-x.com)

### Contacts

Micro-X Limited	Investor Enquiries
<b>Kingsley Hall</b> , Chief Executive Officer <b>Rebecca Puddy</b> , Head of Corporate Communications Tel: +61 8 7099 3966 Email: <a href="mailto:media@micro-x.com">media@micro-x.com</a>	<b>David Allen / John Granger</b> Hawkesbury Partners Tel: +61 2 9103 9494 Email: <a href="mailto:dallen@hawkesburypartners.com">dallen@hawkesburypartners.com</a> <a href="mailto:jgranger@hawkesburypartners.com">jgranger@hawkesburypartners.com</a>